Age-Related Macular Degeneration: Treating the Whole Patient

Archives of Ophthalmology

Volumn 122, Issue 4, 2004, Pages 648-649

  Tasman, William ^a,b   Rovner, Barry ^a  

^a Wills Eye Hospital ^*

^b WILLS EYE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLINDNESS; COPING BEHAVIOR; EDITORIAL; LOW LEVEL LASER THERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION;

EID: 1842425626     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.4.648     Document Type: Editorial

References (13)

1. Tielsch JA. Vision problems in the US: a report on blindness and vision impairment in adults age 40 and older. In: Prevent Blindness America, Schaumberg, III: Prevent Blindness; 1994.
2. Klein R, Klein BE, Linton KL, DeMets DL. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking. Am J Epidemiol. 1993;137:190-200.
3. O'Shea JG. Age-related macular degeneration: a leading cause of blindness. Med J Aust. 1996;165:561-564,
4. O'Shea JG. Age-related macular degeneration. Postgrad Med J. 1998;74:203-207.
5. Buch H, Vinding T, la Cour M, Nielsen NV, for the Copenhagen City Eye Study. The prevalence and causes of bilateral and unilateral blindness in an elderly urban Danish population. Acta Ophthalmol Scand. 2001;79:441-494.
6. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report [published correction appears in Arch Ophthalmol. 2000;118:488]. Arch OphthalmoL 1999;117:1329-1345.
7. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report [published correction appears in Arch Ophthalmol. 2000;118:488]. Arch OphthalmoL 1999;117:1329-1345.
8. Bressler NM; Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol. 2001;119:198-207.
9. Age-Related Eye Disease Study Research Group. A randomized, placebocontrolled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. Arch Ophthalmol. 2001;119:1417-1435.
10. Brody BL, Gamst AC, Williams RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001;108:1893-1901.
11. Rovner BW, Casten RJ. Activity loss and depression in age-related macular degeneration. Am J Geriatr Psychiatry. 2002;10:305-310.
12. Shmuely-Dulitzki Y, Rovner BW, Zisselman P. The impact of depression on function in low vision elderly patients. Am J Geriatr Psychiatry. 1995;3:325-329.
13. Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol. 2002;120:1041-1044.